Uniseed

NEWS We are delighted that we have been awarded a new US$3.13 million contract extension by the United States Department of Defense (DOD) to fund inclusion of younger adults aged 18–45 in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities. The new funding extends the US$8.18 million already committed by the DOD to support the development of INNA-051. The ongoing Phase Ib study in adults over the age of 60 was initiated in Q2 2024. A DOD funded protocol amendment will support inclusion of individuals aged 18-45 with the aim of informing dose selection for subsequent trials. Results from the study are expected in the Q4 2024. ENA Respiratory CEO, Christophe Demaison, PhD said: “This new funding from DoD is further recognition of the potential of INNA-051 to play a significant role in protecting individuals at risk of serious harm from respiratory viral infections, including those with occupational risk. We are grateful to the DoD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense-JPEO-CBRND and Defense Innovation Unit (DIU) for their continued support.” Read the full release here https://lnkd.in/eYJwGtkE   To keep up to date follow us or for more information visit our website www.enarespiratory.com   #ClinicalTrial #DrugDevelopment #Immunomodulator #RespiratoryDisease

Delighted to announce that ENA Respiratory's Phase Ib clinical study of INNA-051 dry powder formulation in older adults aged 60 and over, is up and running at Scientia Clinical Research in Australia. The single ascending dose phase has been successfully completed, with the multiple ascending dose phase now underway. Results are expected later this year. Read the full release here: https://lnkd.in/gmxPkNMQ To find out more about INNA-051, follow ENA Respiratory or visit www.enarespiratory.com   #ClinicalTrial #DrugDevelopment #Immunomodulator #RespiratoryDisease

Kinoxis Therapeutics Pty Ltd is pleased to announce the successful completion of a Series B round of capital raise. A total of $14.5 million funding has been raised through this round, led by key investors Uniseed, UniSuper, University of Sydney, Stoic Venture Capital, Avicella Capital, as well as a number of sophisticated investors.   The funds raised will be used to support Phase 2 programs for Kinoxis’ lead drug candidate, KNX100, which addresses behavioural and psychological symptoms across multiple indications, including agitation and aggression in dementia and several substance use disorders.   One of the supported programs is CARES-X, a phase 2 clinical study commencing this month. First of its kind in Australia, CARES-X will be conducted across 8 sites with 60 patients, examining the safety, tolerability and efficacy of KNX100 when used as a treatment of agitation in dementia patients.   Agitation and aggression in dementia not only have a profound impact on caregivers, but also are often the driver for the transition to assisted living facilities, resulting in a significant economic burden to the public healthcare system. Commenting on the fundraise and the CARES-X study, Kinoxis CEO Hugh Alsop said:” “This injection of funding comes at an important time. We are targeting a significant unmet treatment need for dementia patients, potentially broadening the options for them to maintain a higher quality of life. This is a new and highly promising area of development for KNX100, and we are grateful to have had the strong support from our major investors.”   Thanks also to Lis Boyce at Piper Alderman and the team at Bio101 for their support through this round.   For more details on the Series B fund raise and the CARES-X study, read the full press release via this link: https://lnkd.in/gw9Htpem #AgitationinDementia #SubstanceUseDisorder #SeriesB #BiotechInvestment

Kinoxis Therapeutics Pty Ltd is pleased to share that our CEO, Hugh Alsop has been announced as the inaugural recipient of the CEO of the Year award at The Brooker Prize gala.   The CEO of the Year award recognises individuals who have made a significant commercial, educational, member-driven or research-based contribution to their organisation or the sector. Thank you Brooker Consulting for this prestigious acknowledgment of Hugh’s contribution to the biotech and life sciences industry. As seen in this photo: John Kurek, Investor Director at Uniseed and Dr Rachel C., Principal of Brooker Consulting with Kinoxis CEO, Hugh Alsop.   #leadershipaward #biotech #lifesciences

Diraq is pleased to announce the second close of our oversubscribed Series A-2 investment round of USD $22 million.   We welcome our new investors Main Sequence, Taronga Ventures, Uniseed, UniSuper, and CoAct Capital, alongside Allectus Capital, Quantonation, UNSW Sydney and John Higgins Family Investments, and look forward to partnering together as we work towards delivering the world's first fault-tolerant quantum computer.   Read more here: https://lnkd.in/gbcdWksU   Andrew Dzurak Stefanie Tardo Dr. Lasantha T. Arne Laucht Andre Saraiva Chris Escott Wee Han Lim Henry Yang Bill Bartee Alejandra Romero Avi Naidu Jonathan Hannam Anjalika Singh Paul Butler Laura Droessler-Dansie Kate Bennett Eriksson James Douglas Ash Lambert Matthew Gould Jason Cheong William Zeng Christophe Jurczak Eliathamby Ambikairajah Stephen Rodda Dax Kukulj Stuart White William Jeffrey Hemang Shah Jeremy Manuelpillai

Big news! BioScout just won the "Best in Horticulture" award at the Australian Agritech Association Awards last night! We're beyond excited to see our innovative technology making waves in crop disease management. A huge shoutout to our amazing team and the farmers who trust our solutions. Here’s to a future of healthier crops and sustainable farming! #Agritech #Innovation #Agriculture #SustainableFarming #BioScout Lewis Collins Karla Gartshore (AgTech, BioScout, Disease Detection)

We are very pleased to announce our partnership with Bupa and Honeysuckle Health to expand access to our #digitaltherapeutic for Cardiac Rehabilitation.  Bupa is one of Australia’s largest private health insurers and is a healthcare partner to more than 4.3 million of its customers.  This partnership has the potential to make a significant difference in improving cardiac rehab participation rates, quality of life and outcomes for people living with heart disease. Health service company Honeysuckle Health will deliver the program via their team of registered nurses and virtual healthcare specialists. Cardihab CEO Helen Souris says, "Establishing valuable partnerships with key healthcare stakeholders such as Bupa and Honeysuckle Health is the key to delivering quality virtual healthcare to people at the time and place that works conveniently for them.”  “Our long-term goal is to radically increase equitable access to cardiac rehabilitation and preventative healthcare through proven virtual models. We are thrilled that Bupa members can now access our digital cardiac rehabilitation program through this initial pilot.” Bupa Director of Connected Care Adam Simson says, “We’re always looking for ways to increase access to healthcare and offer our members greater choice around where their care takes place. “We’re thrilled to be partnering with Cardihab to help expand our care offerings that improve health outcomes.”     Honeysuckle Health CEO, Rhod McKensey is equally excited. “Having already partnered with Cardihab and seen outstanding results to date, the Honeysuckle Health team is thrilled to now be able to deliver the program to Bupa members and help them on their recovery journey.” Learn more about this service here 👉 https://lnkd.in/gwiBmASt #partnerships #improvingaccess #equitableaccess #digitalhealth #healthcare Tim Fortin John Rivers Philip Barnes Hugh Dawkins Paul Butler Christine Kwong RN CHIA George Lambrou Caroline White Maha Khalaf Alanna DeGraaf ANDHealth

Join us for an insightful webinar as Laura Droessler-Dansie, Investment Manager from Uniseed, takes you through the world of early stage funding!   💸 Find out what it takes to receive external funding to help commercialise your technology. 💡 Learn some of the challenges on the path to investment. 🌱 Share in tips for budding entrepreneurs. 📈 Hear of some of the success stories of Uniseed's investments.   Looking to navigate the world of early-stage funding? Join our Researcher Community Group for access to register! https://lnkd.in/gbQ7Cf9K

Kinoxis Therapeutics partners with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to evaluate lead compound, KNX100 for alcohol use disorder, under an executed Clinical Trial Agreement (CTA). Did you know that alcohol is one of the leading causes of preventable deaths, claiming 3 million lives worldwide every year? Globally, it is estimated that over 250 million individuals meet the criteria for alcohol use disorder. Despite this, current medications to treat the disorder are limited. Kinoxis’ lead candidate, KNX100, is being developed as a transdiagnostic treatment for substance use disorders. As part of the collaboration, the NIAAA will conduct an initial pharmacodynamic and pharmacokinetic interaction study of KNX100 and ethanol, as the first step to develop a safe and effective treatment for alcohol use disorder. This Phase 1 clinical trial will be conducted under a CTA between NIAAA and Kinoxis and is pending Institutional Review Board (IRB) approval and Investigational New Drug (IND) approval by the U.S. Food and Drug Administration. The collaboration between Kinoxis and the NIAAA marks a significant advancement in the progression of KNX100 for the treatment of alcohol use disorder. Read more about the partnership here: https://lnkd.in/gQmuVQu9 Learn more about Kinoxis Therapeutics here: https://lnkd.in/gAjjDEM4 #AlcoholUseDisorder #SubstanceUseDisorders #NovelTherapies #ClinicalTrial #Biotech #NIH #NIAAA #Biotechnology The National Institutes of Health